My research focuses on molecular pathology of pancreatic cancer, in particular its development and progression. We are using this knowledge to develop biomarkers for early, non-invasive detection of this malignancy in urine specimens.
Our research aims to understand the epigenetic regulation of transposable elements and how their dysregulation contributes to the generation and development of cancer. In particular, we investigate their roles as gene regulators and triggers of anti-tumour immunity in blood cancers.
My group aims to discover the epigenetic changes taking place during cancer initiation and develop potential drugs that can prevent these changes which may be abnormal but reversible, before many damaging mutations occur.
We are investigating how drug resistance evolves in bowel and gastro-oesophageal cancers, how these tumour types can be treated more effectively through novel immunotherapies and targeted drugs, and how treatment sensitivity and resistance can be predicted.
Our lab aims to improve treatments for women with ovarian cancer, particularly those that are resistant to chemotherapy. We are interested in developing therapies that can adapt to the evolution of chemotherapy resistance over time such as Adaptive Therapy.
My lab aims to understand the mechanisms that underlie numerical and structural chromosome aberrations in cancer at a molecular level, which also involves understanding how normal cells replicate and segregate their genomes.
My group studies how RNA-mediated mechanisms, in particular long noncoding RNAs, regulate cell division and how dysregulation of these processes leads to genome instability and cancer.
I have broad research interests and experience in bioinformatics, cancer genomics and data analytics. These research areas mainly involve developing and applying bioinformatics and computational approaches to analyse large-scale cancer datasets to uncover novel diagnostic and prognostic biomarkers. I also lead the Cancer Research UK Barts Centre Bioinformatics Core Facility.
My group combines mathematics, computer simulations and genomic information to study evolutionary processes. We aim to understand how a tumour’s evolutionary history is reflected in its genome, how evolution can be quantified in individual tumours and how this information predicts future evolution.
The aim of my research project is to identify and functionally characterise candidate disease genes in familial leukaemia.
I am providing bioinformatics support for several projects focusing on squamous cell carcinoma. This generally involves developing bioinformatics pipelines for large-scale cancer datasets and utilising computational approaches for analysis, with the overall aim being to uncover novel diagnostic and prognostic biomarkers.
My research project is focused on understanding the impact of centrosome amplification in cancer, in particular the role of extra centrosomes in tumour evolution.
My research interest focuses on risk stratification signatures for Barrett’s oesophagus progression to cancer using high throughput multiplexed imaging, bioinformatics, shallow whole genome sequencing, and spatial transcriptomics.
My research focuses on understanding the relationship between chromosome instability mechanisms and tumour cells’ resistance to therapies.
I investigate mathematical properties of somatic evolution in the context of both cancerous and healthy tissue.